Cardiac Marker Global Market Report 2024

The cardiac marker market has grown rapidly in recent years. It will grow from $10.4 billion in 2023 to $11.55 billion in 2024 at a compound annual growth rate (CAGR) of 11.0%. The growth observed in the previous period can be attributed to several key factors. These include a notable increase in the incidence of cardiovascular diseases, the demographic shift toward an aging population, heightened awareness programs and health screenings aimed at cardiovascular risks, the integration of biomarkers into clinical practice for improved diagnostics, and the establishment of stringent regulatory standards and guidelines governing cardiac diagnostics. These factors collectively contributed to the growth witnessed during that timeframe within the realm of cardiac markers and diagnostics.

The cardiac marker market is expected to see rapid growth in the next few years. It will grow to $18.08 billion in 2028 at a compound annual growth rate (CAGR) of 11.8%. Anticipated growth in the upcoming period is expected to stem from several influential factors. These encompass the escalating burden associated with lifestyle-related diseases, the increasing adoption of remote monitoring and telemedicine practices, the shift towards personalized medicine and precision diagnostics, the widespread adoption of point-of-care testing (POCT), and a surge in collaborations and partnerships within the healthcare landscape.

The projected surge in the cardiac marker market is strongly driven by the escalating prevalence of cardiac diseases. This category comprises conditions affecting the heart's structure or functionality, leading to a spectrum of medical issues. Cardiac markers serve as crucial tools in diagnosing and monitoring various heart-related conditions such as heart attacks, angina, heart failure, and other cardiovascular diseases. Consequently, the demand for diagnostic tests involving cardiac markers has seen a notable increase. For instance, the British Heart Foundation reported an alarming increase of 30,000 deaths from coronary heart disease in England from the pandemic's onset to August 2022. Moreover, a staggering 346,000 individuals were on cardiac waiting lists by August 2022. Hence, the escalating prevalence of cardiac diseases significantly fuels the growth of the cardiac marker market.

The escalating demand within diagnostic centers stands as a pivotal driver for the cardiac marker market's growth trajectory. Diagnostic centers, specialized healthcare facilities, play a crucial role in conducting a range of medical tests and procedures aimed at identifying and monitoring health conditions. The incorporation of cardiac markers in these centers offers critical insights for timely and accurate diagnoses, risk assessment, and tailored treatment strategies, ultimately leading to improved cardiovascular health outcomes. For instance, according to GOV.UK, the year 2022 witnessed 73 diagnostic centers conducting an additional 30,000 tests per week, with projections suggesting a potential increase to 160 community diagnostic centers by 2025. Consequently, the surging demand within diagnostic centers is steering the growth of the cardiac marker market.

Innovation emerges as a significant trend gaining traction within the cardiac marker market, with major players focusing on pioneering solutions to fortify their market presence. For example, MiRxes, a Singapore-based biotechnology firm, recently validated a microRNA-based diagnostic test designed for early detection and diagnosis of illnesses. The forthcoming commercialization of this test will complement MiRxes' portfolio of blood tests for various conditions, aiming to alleviate the mounting clinical and socioeconomic burdens associated with life-threatening diseases, including cancer and cardio-pulmonary disorders.

Leading companies in the cardiac marker market prioritize innovative products, such as high-sensitivity troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers, to drive market revenue. These biomarkers play crucial roles in diagnosing, categorizing, and treating cardiovascular ailments. For instance, in October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a prominent China-based medical equipment and solutions provider, launched troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTn assay surpasses minimal sensitivity, accuracy, and reliability requirements, aiding in identifying myocardial damage. These advanced products aim to enhance treatment approaches for cardiovascular diseases, offering dependable solutions to improve patient outcomes in both cardiovascular and related health contexts.

In April 2023, Abbott Laboratories, a US-based healthcare company acquired Cardiovascular Systems Inc. for an undisclosed amount. With this acquisition, Abbott will be able to better serve patients with peripheral and coronary artery disease by offering a novel and cutting-edge therapy for those with complicated cardiovascular disease. Through this acquisition, Abbott is able to expand the range of cutting-edge vascular devices it offers doctors, giving them more resources to assist patients. Cardiovascular Systems Inc. a US-based medical technology company.

Major companies operating in the cardiac marker market report are Abbott Laboratories Inc., Siemens AG, Danaher Corporation, BioMérieux SA, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Guangzhou Wondifo Biotech Co. Ltd., Creative Diagnostics, PerkinElmer Inc., Tosoh Corporation, Quidel Corporation, Randox Laboratories Ltd., Getinge Group, LSI Medience Corporation, Ortho Clinical Diagnostics, DiaSorin, Advanced Sterilization Products Services Inc., 3M Company, Belimed AG, Cantel Medical Corporation, MELAG Medizintechnik GmbH & Co. KG., Atom Medical Corporation, Bionet America Inc., Bistos Inc., CareFusion Corporation, Clinical Innovations LLC, Abcam plc, General Electric Company.

North America was the largest region in the cardiac marker market in 2023. The regions covered in the cardiac marker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac marker market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary types of cardiac markers encompass troponin, creatine kinase-MB (CK-MB), B-type natriuretic peptide (BNP), myoglobin, and various other biomarkers. Troponin, a protein released upon heart muscle damage, stands as a pivotal marker widely used for diagnosing and monitoring heart-related conditions. Diverse products in the realm of cardiac markers include reagents, instruments, and various detection methodologies such as chemiluminescence, immunofluorescence, immunochromatography, and ELISA. These markers find application across multiple indications, including myocardial infarction, congestive heart failure, acute coronary syndrome, among others. End users encompass laboratory testing facilities, hospital labs, reference labs, contract testing labs, point-of-care testing facilities, and academic institutions, where these markers play a vital role in cardiac diagnostics and monitoring.

The cardiac marker market research report provides Cardiac marker market statistics, including global market size, regional shares, competitors with a cardiac marker market share, detailed cardiac marker market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac marker industry. This cardiac marker market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiac marker market consists of sales of C-reactive protein (CRP) and Ischemia-modified albumin (IMA). Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.